Nippon India Pharma Fund
NAV
₹627.72
as of 6 Oct 2026
Nippon India Pharma Fund is an open-ended Sectoral/ Thematic scheme from Nippon India Mutual Fund managing ₹9,479 crore (as of 31 Aug 2026). Its Direct-plan NAV is ₹627.72 as of 6 Oct 2026. The expense ratio is 0.99% a year. Managed by Sailesh Raj Bhan. This page is factual data only – it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.99% / yr
- as of 31 Aug 2026
- Fund size
- ₹9,479 crore
- as of 31 Aug 2026
- Exit load
- 1%
- SIP available
- Yes
- Launched
- 5 Jun 2004
- ISIN
- INF204K01I50
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from nyvo’s own NAV data.
Rebased to 100data to 5 Oct 2026Benchmark: Nifty Pharma TRI
Nippon India Pharma Fund
₹187
+87% on ₹100 over 5.0 yrs
Sectoral/ Thematic average
₹198
+98% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | -1.56% | -4.47% | +2.91 |
| 6 months | 12.88% | 7.56% | +5.32 |
| 1 year | 10.27% | -0.10% | +10.37 |
| 3 years (CAGR) | 17.65% | 12.32% | +5.33 |
| 5 years (CAGR) | 12.88% | 11.84% | +1.04 |
Category average across 119 funds, as of 5 Oct 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible – read that number first.
1-year holding periods
- Worst
- -9.2%
- Median
- 13.5%
- Best
- 61.5%
49 windows over the last 60 months, stepped monthly; 78% ended positive. Worst window began 3 Jan 2022. Windows overlap – this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 17.8%
- Median
- 21.9%
- Best
- 26.4%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 3 Oct 2023. Windows overlap – this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.89
- Sharpe ratio (5Y)
- 0.57
- Sortino ratio (3Y)
- 1.48 vs category 1.63
- Standard deviation (3Y)
- 14.77%
- Beta (3Y)
- 0.88
- Alpha (3Y)
- -0.75%
- Deepest fall (5Y)
- -16.58%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high – how deep and for how long is what a drawdown feels like.
Deepest fall
-14.2%
Right now
-4.9% below peak
Ahead of its benchmark in 33% of months (window: 3y, monthly) – benchmark: Nifty Pharma TRI, name shown only.
Where the money actually is
Equity
98.0%
Cash
2.0%
Whole-portfolio split, as of 31 Aug 2026.
What it owns
40 positions · top 10 = 56.8%
Market-cap mix
Large 30.6%Mid 38.8%Small 28.1%Other 2.4%
as of 31 Aug 2026
Holdings by sector
Healthcare(10 in top 10)98.0%
- Sun Pharmaceuticals Industries Ltd12.37%
- Divi's Laboratories Ltd7.00%
- Lupin Ltd6.43%
- Cipla Ltd6.09%
- Apollo Hospitals Enterprise Ltd5.15%
- Dr Reddy's Laboratories Ltd4.93%
- Mankind Pharma Ltd4.09%
- Sai Life Sciences Ltd3.94%
- Ajanta Pharma Ltd3.47%
- GlaxoSmithKline Pharmaceuticals Ltd3.31%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Aug 2026. Portfolio turnover 13.8% vs category 37.4% a year.
The businesses it owns
- P/E (trailing)
- 39.2 vs category 25.9
- P/B
- 5.8 vs category 3.9
- Dividend yield
- 0.8% vs category 1.1%
- Net margin
- 16.0% vs category 15.4%
- Earnings growth
- 10.3%
- Avg market cap
- ₹68,860 crore
Money in, money out
- Net flow, 12 months
- −₹59 cr
- Net flow, 3 months
- +₹67 cr
as of 31 Aug 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of Nippon India Pharma Fund?
- ₹627.72 per unit as of 6 Oct 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of Nippon India Pharma Fund?
- 0.99% a year for the Direct plan, as of 31 Aug 2026.
- How large is Nippon India Pharma Fund?
- ₹9,479 crore under management as of 31 Aug 2026, in the Sectoral/ Thematic category.
- How risky is Nippon India Pharma Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of Nippon India Pharma Fund?
- 12.88% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 11.84%. Past returns do not predict future returns.
- What is the worst 3-year return of Nippon India Pharma Fund?
- 17.8% a year – the weakest of 25 overlapping 3-year holding periods, beginning 3 Oct 2023. The median was 21.9% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages Nippon India Pharma Fund?
- Sailesh Raj Bhan, managing this fund for 21.4 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund – growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,338 crore
- ICICI Prudential Business Cycle Fund₹15,873 crore
- HDFC Manufacturing Fund₹10,752 crore
- Tata Digital India Fund₹10,322 crore
- Franklin India Opportunities Fund₹9,344 crore
- ICICI Prudential Infrastructure Fund₹8,558 crore
- Nippon India Power & Infra Fund₹8,137 crore
- Nippon India Banking & Financial Services Fund₹7,910 crore
Data: nyvo research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty Pharma TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.